Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) is a rare form of gastric carcinoma (seen in approximately 10% of cases) with a male predominance, characterized by a latent EBV infection in gastric carcinoma cells, diffuse-type histology, a proximal location (in the body and cardia of the stomach) and a relatively favorable prognosis.
Biomarker and diagnostic research for Epstein-Barr virus-associated gastric carcinoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
67 publications have been identified in PubMed for Epstein-Barr virus-associated gastric carcinoma. Research spans Basic Science / Preclinical (55%), Epidemiology / Natural History (13%), and Review / Meta-Analysis (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 37 |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 5:30 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Epstein-Barr virus-associated gastric carcinoma
Disease patterns and progression | 9 | 13% |
Research summaries | 7 | 10% |
Testing and diagnosis research | 6 | 9% |
Patient case studies | 3 | 4% |
New treatment approaches | 3 | 4% |
Clinical study results | 2 | 3% |
Huang X (2026). [PMID: 39903432](https://pubmed.ncbi.nlm.nih.gov/39903432/). *Biochemical genetics*. [Basic Science / Preclinical]
Fujita Y (2026). [PMID: 41830468](https://pubmed.ncbi.nlm.nih.gov/41830468/). *Genes, chromosomes & cancer*. [Diagnostic / Biomarker]
Preston-Alp S (2026). [PMID: 41665354](https://pubmed.ncbi.nlm.nih.gov/41665354/). *mBio*. [Basic Science / Preclinical]
Gong LP (2026). [PMID: 41504772](https://pubmed.ncbi.nlm.nih.gov/41504772/). *Journal of cancer research and clinical oncology*. [Basic Science / Preclinical]
Zhao MH (2026). [PMID: 41491429](https://pubmed.ncbi.nlm.nih.gov/41491429/). *Journal of molecular histology*. [Gene Therapy / Novel Therapeutics]
Koriyama C (2026). [PMID: 41928280](https://pubmed.ncbi.nlm.nih.gov/41928280/). *Infect Agent Cancer*. [Diagnostic / Biomarker]
Xia P (2026). [PMID: 41877627](https://pubmed.ncbi.nlm.nih.gov/41877627/). *Acta Biochim Biophys Sin (Shanghai)*. [Diagnostic / Biomarker]
Huo RZ (2026). [PMID: 41940351](https://pubmed.ncbi.nlm.nih.gov/41940351/). *iScience*. [Diagnostic / Biomarker]
Abu-Khudir R (2026). [PMID: 42143203](https://pubmed.ncbi.nlm.nih.gov/42143203/). *Arch Virol*. [Review / Meta-Analysis]
Gallardo J (2026). [PMID: 41580207](https://pubmed.ncbi.nlm.nih.gov/41580207/). *Human pathology*. [Basic Science / Preclinical]
AI-curated news mentioning Epstein-Barr virus-associated gastric carcinoma
Updated Jul 28, 2026
A new study discusses postoperative adjuvant treatment decisions for early Epstein-Barr virus-associated gastric cancer. This research may influence treatment protocols and improve patient outcomes in this specific cancer type.